ArticleOPEN ACCESS

Targeting the epigenome in malignant pleural mesothelioma

Translational Lung Cancer Research
DOI: 10.21037/tlcr.2017.06.06
39Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

Malignant pleural mesotheliomas (MPM) are notoriously refractory to conventional treatment modalities. Recent insights regarding epigenetic alterations in MPM provide the preclinical rationale for the evaluation of novel combinatorial regimens targeting the epigenome in these neoplasms.

Author supplied keywords

Cite

CITATION STYLE

APA

McLoughlin, K. C., Kaufman, A. S., & Schrump, D. S. (2017, June 1). Targeting the epigenome in malignant pleural mesothelioma. Translational Lung Cancer Research. AME Publishing Company. https://doi.org/10.21037/tlcr.2017.06.06

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free